Recombinant oncolytic adenovirus and application thereof
The invention provides a recombinant oncolytic adenovirus and application thereof, the recombinant oncolytic adenovirus is constructed based on a type-5 adenovirus, the genome of the recombinant oncolytic adenovirus comprises a nucleotide sequence for coding a BiTE antibody or an antibody fragment,...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WU HUAN WANG QIUMAN KONG BEIHUA SONG KUN YUAN CUNZHONG ZHANG QING |
| description | The invention provides a recombinant oncolytic adenovirus and application thereof, the recombinant oncolytic adenovirus is constructed based on a type-5 adenovirus, the genome of the recombinant oncolytic adenovirus comprises a nucleotide sequence for coding a BiTE antibody or an antibody fragment, and the nucleotide sequence for coding the BiTE antibody or the antibody fragment is located between a virus element mCMV and a virus element MCS-3Flag. According to the recombinant oncolytic adenovirus, the targeting of T cells to tumor cells is improved, adverse reactions caused by systemic administration of BiTE are avoided, and the killing effect of the oncolytic adenovirus on solid tumors is improved through the activation effect of BiTE on an immune microenvironment.
本发明提供一种重组溶瘤腺病毒及其应用，该重组溶瘤腺病毒基于5型腺病毒构建，其基因组中包含编码BiTE抗体或抗体片段的核苷酸序列，所述编码BiTE抗体或抗体片段的核苷酸序列位于病毒的元件mCMV和MCS-3Flag之间。本发明的重组溶瘤腺病毒提高了T细胞对肿瘤细胞的靶向性、并且避免了BiTE全身用药引起的不良反应，而且通过BiTE对免疫微环境的激活作用，增加了溶瘤腺病毒对实体瘤的杀伤效果。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN113969266A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN113969266A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN113969266A3</originalsourceid><addsrcrecordid>eNrjZLAISk3Oz03KzEvMK1HIz0vOz6ksyUxWSExJzcsvyywqLVZIzEtRSCwoyMlMTizJzM9TKMlILUrNT-NhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGxpZmlkZmZo7GxKgBAFyHLw8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Recombinant oncolytic adenovirus and application thereof</title><source>esp@cenet</source><creator>WU HUAN ; WANG QIUMAN ; KONG BEIHUA ; SONG KUN ; YUAN CUNZHONG ; ZHANG QING</creator><creatorcontrib>WU HUAN ; WANG QIUMAN ; KONG BEIHUA ; SONG KUN ; YUAN CUNZHONG ; ZHANG QING</creatorcontrib><description>The invention provides a recombinant oncolytic adenovirus and application thereof, the recombinant oncolytic adenovirus is constructed based on a type-5 adenovirus, the genome of the recombinant oncolytic adenovirus comprises a nucleotide sequence for coding a BiTE antibody or an antibody fragment, and the nucleotide sequence for coding the BiTE antibody or the antibody fragment is located between a virus element mCMV and a virus element MCS-3Flag. According to the recombinant oncolytic adenovirus, the targeting of T cells to tumor cells is improved, adverse reactions caused by systemic administration of BiTE are avoided, and the killing effect of the oncolytic adenovirus on solid tumors is improved through the activation effect of BiTE on an immune microenvironment.
本发明提供一种重组溶瘤腺病毒及其应用，该重组溶瘤腺病毒基于5型腺病毒构建，其基因组中包含编码BiTE抗体或抗体片段的核苷酸序列，所述编码BiTE抗体或抗体片段的核苷酸序列位于病毒的元件mCMV和MCS-3Flag之间。本发明的重组溶瘤腺病毒提高了T细胞对肿瘤细胞的靶向性、并且避免了BiTE全身用药引起的不良反应，而且通过BiTE对免疫微环境的激活作用，增加了溶瘤腺病毒对实体瘤的杀伤效果。</description><language>chi ; eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220125&DB=EPODOC&CC=CN&NR=113969266A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220125&DB=EPODOC&CC=CN&NR=113969266A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WU HUAN</creatorcontrib><creatorcontrib>WANG QIUMAN</creatorcontrib><creatorcontrib>KONG BEIHUA</creatorcontrib><creatorcontrib>SONG KUN</creatorcontrib><creatorcontrib>YUAN CUNZHONG</creatorcontrib><creatorcontrib>ZHANG QING</creatorcontrib><title>Recombinant oncolytic adenovirus and application thereof</title><description>The invention provides a recombinant oncolytic adenovirus and application thereof, the recombinant oncolytic adenovirus is constructed based on a type-5 adenovirus, the genome of the recombinant oncolytic adenovirus comprises a nucleotide sequence for coding a BiTE antibody or an antibody fragment, and the nucleotide sequence for coding the BiTE antibody or the antibody fragment is located between a virus element mCMV and a virus element MCS-3Flag. According to the recombinant oncolytic adenovirus, the targeting of T cells to tumor cells is improved, adverse reactions caused by systemic administration of BiTE are avoided, and the killing effect of the oncolytic adenovirus on solid tumors is improved through the activation effect of BiTE on an immune microenvironment.
本发明提供一种重组溶瘤腺病毒及其应用，该重组溶瘤腺病毒基于5型腺病毒构建，其基因组中包含编码BiTE抗体或抗体片段的核苷酸序列，所述编码BiTE抗体或抗体片段的核苷酸序列位于病毒的元件mCMV和MCS-3Flag之间。本发明的重组溶瘤腺病毒提高了T细胞对肿瘤细胞的靶向性、并且避免了BiTE全身用药引起的不良反应，而且通过BiTE对免疫微环境的激活作用，增加了溶瘤腺病毒对实体瘤的杀伤效果。</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAISk3Oz03KzEvMK1HIz0vOz6ksyUxWSExJzcsvyywqLVZIzEtRSCwoyMlMTizJzM9TKMlILUrNT-NhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGxpZmlkZmZo7GxKgBAFyHLw8</recordid><startdate>20220125</startdate><enddate>20220125</enddate><creator>WU HUAN</creator><creator>WANG QIUMAN</creator><creator>KONG BEIHUA</creator><creator>SONG KUN</creator><creator>YUAN CUNZHONG</creator><creator>ZHANG QING</creator><scope>EVB</scope></search><sort><creationdate>20220125</creationdate><title>Recombinant oncolytic adenovirus and application thereof</title><author>WU HUAN ; WANG QIUMAN ; KONG BEIHUA ; SONG KUN ; YUAN CUNZHONG ; ZHANG QING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN113969266A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>WU HUAN</creatorcontrib><creatorcontrib>WANG QIUMAN</creatorcontrib><creatorcontrib>KONG BEIHUA</creatorcontrib><creatorcontrib>SONG KUN</creatorcontrib><creatorcontrib>YUAN CUNZHONG</creatorcontrib><creatorcontrib>ZHANG QING</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WU HUAN</au><au>WANG QIUMAN</au><au>KONG BEIHUA</au><au>SONG KUN</au><au>YUAN CUNZHONG</au><au>ZHANG QING</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Recombinant oncolytic adenovirus and application thereof</title><date>2022-01-25</date><risdate>2022</risdate><abstract>The invention provides a recombinant oncolytic adenovirus and application thereof, the recombinant oncolytic adenovirus is constructed based on a type-5 adenovirus, the genome of the recombinant oncolytic adenovirus comprises a nucleotide sequence for coding a BiTE antibody or an antibody fragment, and the nucleotide sequence for coding the BiTE antibody or the antibody fragment is located between a virus element mCMV and a virus element MCS-3Flag. According to the recombinant oncolytic adenovirus, the targeting of T cells to tumor cells is improved, adverse reactions caused by systemic administration of BiTE are avoided, and the killing effect of the oncolytic adenovirus on solid tumors is improved through the activation effect of BiTE on an immune microenvironment.
本发明提供一种重组溶瘤腺病毒及其应用，该重组溶瘤腺病毒基于5型腺病毒构建，其基因组中包含编码BiTE抗体或抗体片段的核苷酸序列，所述编码BiTE抗体或抗体片段的核苷酸序列位于病毒的元件mCMV和MCS-3Flag之间。本发明的重组溶瘤腺病毒提高了T细胞对肿瘤细胞的靶向性、并且避免了BiTE全身用药引起的不良反应，而且通过BiTE对免疫微环境的激活作用，增加了溶瘤腺病毒对实体瘤的杀伤效果。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN113969266A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | Recombinant oncolytic adenovirus and application thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A37%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WU%20HUAN&rft.date=2022-01-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN113969266A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |